TSFAE01a:	Overall Summary of Subjects With Treatment-emergent Adverse Events; Safety Analysis Set (Study jjcs - core)						
 	Active Study Agent 	Active Study Agent 	 	Risk Difference (%) (95% CI) 	Risk Difference (%) (95% CI) 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Placebo 	Xanomeline High Dose vs Placebo 	Xanomeline Low Dose vs Placebo 	
Event, n (%) 	N=53 	N=73 	N=59 	  	  	
SAE 	47 (88.7%) 	54 (74.0%) 	37 (62.7%) 	26.0 (11.0, 41.0) 	11.3 (-4.7, 27.2) 	
With fatal outcome 	0 	1 (1.4%) 	1 (1.7%) 	-1.7 (-5.0, 1.6) 	-0.3 (-4.6, 3.9) 	
Life-threatening 	0 	1 (1.4%) 	1 (1.7%) 	-1.7 (-5.0, 1.6) 	-0.3 (-4.6, 3.9) 	
Requiring or prolonging hospitalization 	2 (3.8%) 	2 (2.7%) 	3 (5.1%) 	-1.3 (-8.9, 6.3) 	-2.3 (-9.1, 4.4) 	
Resulting in persistent or significant disability/incapacity 	0 	1 (1.4%) 	0 	0.0 (0.0, 0.0) 	1.4 (-1.3, 4.0) 	
Congenital anomaly or birth defect 	0 	0 	0 	0.0 (0.0, 0.0) 	0.0 (0.0, 0.0) 	
Other 	47 (88.7%) 	54 (74.0%) 	37 (62.7%) 	26.0 (11.0, 41.0) 	11.3 (-4.7, 27.2) 	
 	 	 	 	 	 	
AE leading to permanent discontinuation of study treatment 	23 (43.4%) 	20 (27.4%) 	18 (30.5%) 	12.9 (-4.9, 30.7) 	-3.1 (-18.7, 12.5) 	
 	 	 	 	 	 	
AE leading to dose modification of study treatment 	51 (96.2%) 	56 (76.7%) 	40 (67.8%) 	28.4 (15.5, 41.4) 	8.9 (-6.5, 24.3) 	
Interruption of study treatment 	28 (52.8%) 	35 (47.9%) 	19 (32.2%) 	20.6 (2.7, 38.6) 	15.7 (-0.8, 32.3) 	
Reduction of study treatment 	24 (45.3%) 	26 (35.6%) 	17 (28.8%) 	16.5 (-1.2, 34.2) 	6.8 (-9.1, 22.7) 	
Dose Rate Reduced 	31 (58.5%) 	27 (37.0%) 	15 (25.4%) 	33.1 (15.8, 50.4) 	11.6 (-4.1, 27.2) 	
Dose Increased 	27 (50.9%) 	25 (34.2%) 	18 (30.5%) 	20.4 (2.6, 38.3) 	3.7 (-12.3, 19.8) 	
Unknown 	24 (45.3%) 	31 (42.5%) 	13 (22.0%) 	23.2 (6.2, 40.3) 	20.4 (4.9, 35.9) 	
 	 	 	 	 	 	
Any AEa 	51 (96.2%) 	62 (84.9%) 	42 (71.2%) 	25.0 (12.4, 37.7) 	13.7 (-0.4, 27.9) 	
Mild 	17 (32.1%) 	15 (20.5%) 	23 (39.0%) 	-6.9 (-24.6, 10.8) 	-18.4 (-34.0, -2.9) 	
Moderate 	31 (58.5%) 	35 (47.9%) 	16 (27.1%) 	31.4 (13.9, 48.8) 	20.8 (4.7, 37.0) 	
Severe 	3 (5.7%) 	12 (16.4%) 	3 (5.1%) 	0.6 (-7.8, 8.9) 	11.4 (1.2, 21.5) 	

a Dose modifications as collected on the AE CRF are presented. Subjects may be counted once for each modification type. 	
a Dose modifications as collected on the AE CRF are presented. Subjects may be counted once for each modification type.	
a Dose modifications as collected on the AE CRF are presented. Subjects may be counted once for each modification type.	
a Dose modifications as collected on the AE CRF are presented. Subjects may be counted once for each modification type.	
a Dose modifications as collected on the AE CRF are presented. Subjects may be counted once for each modification type.	
a Dose modifications as collected on the AE CRF are presented. Subjects may be counted once for each modification type.	
b The event experienced by the subject with the worst severity is used. 	b The event experienced by the subject with the worst severity is used.	b The event experienced by the subject with the worst severity is used.	b The event experienced by the subject with the worst severity is used.	b The event experienced by the subject with the worst severity is used.	b The event experienced by the subject with the worst severity is used.